Analyst Price Target is $6.13
▲ +437.28% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for RenovoRx in the last 3 months. The average price target is $6.13, with a high forecast of $8.25 and a low forecast of $4.00. The average price target represents a 437.28% upside from the last price of $1.14.
Current Consensus is
Moderate Buy
The current consensus among 3 contributing investment analysts is to moderate buy stock in RenovoRx. This rating has held steady since October 2023, when it changed from a Buy consensus rating.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Read More